Bioavailability Evaluation of a New Compound Bone Peptide Formula

Abstract

: To investigate the contents of hydroxyproline (Hyp) and Glycine-Proline- Hydroxyproline (Gly-Pro-Hyp) in the serum of C57/BL mice after the new compound bone peptide formula was gavaged. The bioavailability and utilization efficiency of the new compound bone peptide formula were evaluated by the contents of above substances in the serum. Moreover, the area under the drug time curve (AUC) was analyzed and compared to explore the effective exposure amount of the new bone peptide formula. The results showed that the contents of Hyp and Gly-Pro-Hyp increased in a dose-dependent manner in the serum. The contents of Hyp and Gly-Pro-Hyp were the highest after 3 h and remained in 24 h. The results indicated that the utilization rate of bone peptide samples was significantly higher than that of bone peptide tablet and bone peptide injection. The AUC of Hyp and Gly-Pro-Hyp in the low-dose bone peptide sample group were significantly higher than that of clinical dose bone peptide samples. AUC of Hyp and Gly-Pro-Hyp in the low-dose bone peptide sample group was significantly higher than those in the clinical dose bone peptide injection and bone peptide tablet groups, indicating that the clinically dose low-dose bone peptide tablet had a good effective exposure to efficacy.